Share on StockTwits

ResMed (NYSE:RMD) CFO Brett Sandercock unloaded 5,000 shares of the stock in a transaction dated Thursday, May 8th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the sale, the chief financial officer now directly owns 66,423 shares of the company’s stock, valued at approximately $3,321,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Deutsche Bank upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Thursday, April 24th. They now have a $52.00 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “equal weight” rating on shares of ResMed in a research note on Thursday, April 24th. They now have a $46.08 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of ResMed in a research note on Monday, March 10th. They now have a $46.00 price target on the stock. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $46.64.

Shares of ResMed (NYSE:RMD) traded up 1.54% on Monday, hitting $51.43. 796,775 shares of the company’s stock traded hands. ResMed has a 52 week low of $41.52 and a 52 week high of $57.34. The stock has a 50-day moving average of $46.89 and a 200-day moving average of $46.87. The company has a market cap of $7.217 billion and a price-to-earnings ratio of 22.22.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $0.63 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.64 by $0.01. The company had revenue of $397.80 million for the quarter, compared to the consensus estimate of $401.00 million. During the same quarter in the prior year, the company posted $0.58 earnings per share. The company’s quarterly revenue was up 3.7% on a year-over-year basis. On average, analysts predict that ResMed will post $2.49 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Tuesday, June 17th. Shareholders of record on Tuesday, May 20th will be paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.94%. The ex-dividend date is Friday, May 16th.

ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.